Upstream Bio (UPB) Income from Continuing Operations (2023 - 2026)
Upstream Bio (UPB) posted quarterly Income from Continuing Operations of 61786000.0 for Q1 2026, down 77.23% year-over-year from 271290342.32 in Q1 2025, and up 69.83% quarter-over-quarter from 204790000.0 in Q4 2025.
Powered by 
Analysis
Upstream Bio (UPB) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Upstream Bio's Income from Continuing Operations history runs 4 years deep, the most recent figure standing at 61786000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 77.23% year-over-year to 61786000.0; the TTM figure through Mar 2026 stood at 483992000.0 (down 146.9% YoY), while the FY2025 annual figure was 305705000.0, down 123.29% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 61786000.0, up from 204790000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 7859000.0 in Q3 2023, with the low at 204790000.0 in Q4 2025.
- The 4-year median for Income from Continuing Operations is 52506000.0 (2023), against an average of 68676090.91.
- Peak annual rise in Income from Continuing Operations reached 76.19% in 2024, while the deepest fall reached 549.96% in 2024.
- Upstream Bio's Income from Continuing Operations stood at 52506000.0 in 2023, then slumped by 76.19% to 92508000.0 in 2024, then plunged by 121.38% to 204790000.0 in 2025, then jumped by 69.83% to 61786000.0 in 2026.
- Business Quant data shows UPB's Income from Continuing Operations at 61786000.0 in Q1 2026, 204790000.0 in Q4 2025, and 133269000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Upstream Bio | 327.95 Mn | 327.95 Mn | -3.29 Mn | -39.71 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -39.71 Mn |
| Mar 31, 2026 | -44.05 Mn |
| Dec 31, 2025 | -42.51 Mn |
| Sep 30, 2025 | -33.73 Mn |
| Jun 30, 2025 | -39.92 Mn |
| Mar 31, 2025 | -31.62 Mn |
| Dec 31, 2024 | -21.24 Mn |
| Sep 30, 2024 | -15.99 Mn |
| Jun 30, 2024 | -17.57 Mn |
| Mar 31, 2024 | -15.06 Mn |
| Dec 31, 2023 | -12.81 Mn |
| Sep 30, 2023 | -7.86 Mn |